Literature DB >> 8449612

Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro.

P Pantazis1, A J Kozielski, J T Mendoza, J A Early, H R Hinz, B C Giovanella.   

Abstract

We have recently shown that the plant alkaloid 20(S)-camptothecin and its derivatives 9-nitro-20(S)-camptothecin(9NC) and 9-amino-20(S)-camptothecin(9AC) inhibit the growth of a variety of human tumors xenografted in nude mice. In this report, we demonstrate that 9NC and 9AC effectively inhibit growth, and subsequently induce regression, of human ovarian tumors grown in nude mice. Tumor regression is accompanied by degenerative changes in the tumor cells as assessed by microscopic observations of histological sections prepared from the tumors. Parallel experiments in vitro show that 9NC inhibits in a similar manner the growth of human ovarian carcinoma cells, regardless of their ability to induce tumors when xenografted in nude mice, and induces similar morphological changes in both non-tumorigenic and tumorigenic cells, as assessed by microscopic observation. Flow cytometry studies show that 9NC-induced growth inhibition of the non-tumorigenic cells is associated with accumulation of these cells in G2. In contrast, 9NC-induced growth inhibition of the tumorigenic cells is associated with the generation of cells containing a reduced DNA content, that is, cells programmed to die. In conclusion, camptothecins appear to be cytostatic for non-tumorigenic, but cytotoxic for tumorigenic cells, an important finding from viewpoints of cell biology, pharmacology and cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449612     DOI: 10.1002/ijc.2910530526

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro.

Authors:  P Pantazis; D Chatterjee; Z Han; J Wyche
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

2.  Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation.

Authors:  Z Han; D Chatterjee; D M He; J Early; P Pantazis; J H Wyche; E A Hendrickson
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

3.  Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.

Authors:  J A Holden; M P Rahn; C J Jolles; S V Vorobyev; I B Bronstein
Journal:  Mol Pathol       Date:  1997-10

Review 4.  Oral topoisomerase 1 inhibitors in adult patients: present and future.

Authors:  H A Gelderblom; M J DE Jonge; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice.

Authors:  Song-Qi Gao; Zheng-Rong Lu; Pavla Kopecková; Jindrich Kopecek
Journal:  J Control Release       Date:  2006-10-27       Impact factor: 9.776

Review 6.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats.

Authors:  Song-Qi Gao; Yongen Sun; Pavla Kopecková; C Matthew Peterson; Jindrich Kopecek
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.200

Review 8.  Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

Authors:  C J Gerrits; M J de Jonge; J H Schellens; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.